CGTN
Chinese President Xi Jinping on Monday arrived in south China's Guangdong Province to begin his inspection tour, his 12th domestic visit this year and his third to Guangdong since the 18th National Congress of the Communist Party of China (CPC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201012005890/en/
"Reform and opening-up" remained the keywords during his three visits to Guangdong in 2012, 2018, 2020, respectively.
Read the original article here .
Protecting cultural legacy
During this visit, President Xi visited cultural and historical landmarks in the city of Chaozhou, including an ancient bridge, an ancient gate tower and a street lined with ancient archways, to check on the restoration and protection of cultural relics, the inheritance of intangible cultural heritage and the development of cultural and tourism resources.
The president has always insisted that the protection and exploration of cultural heritage assets must serve a country's development.
In October 2018, Xi stressed that more importance should be attached to preserving history and culture during urban planning and construction during his visit to Xiguan historical and cultural community in the Liwan District of Guangzhou City, Guangdong Province.
During this National Day and Mid-Autumn Festival holiday, the ancient township of Chaozhou received nearly 2 million tourists with a total revenue of some 890 million yuan, with its cultural charm.
The president underscored that the development of tourism should be based on protection and should not be over-commercialized when he visited the Yungang Grottoes, where he learned about historical and cultural heritage protection efforts in north China's Shanxi Province in May this year.
China's reform and opening-up paragon
President Xi also visited Chaozhou Three-Circle (Group) Co., Ltd., an electronic components and communication device manufacturer, checking out the company's indigenous innovation, production and operation.
In 2019, Guangdong's provincial GDP exceeded 10 trillion yuan (about $1.48 trillion). Under the current poverty threshold, over 1.6 million relatively poor people have reached the alleviation standard, a decisive victory in the battle against poverty.
In December 2012, President Xi visited Guangdong's Shenzhen during his first around-the-country tour after he was elected the CPC leader.
Two years ago, when China marked the 40th anniversary of reform and opening-up, he revisited the city and emphasized the need to keep promoting the process of reform and opening-up.
"I come to visit Shenzhen as it marks the 40th anniversary of reform and opening-up to tell the world that China will not stop its reform and opening-up. China will certainly deliver a bigger miracle that draws worldwide attention," he said.
Shenzhen is an important stop during his latest inspection tour to Guangdong Province.
On Wednesday morning, the president will attend a grand gathering celebrating the 40th anniversary of the establishment of the Shenzhen Special Economic Zone.
On August 26, 1980, the 15th meeting of the Standing Committee of the fifth National People's Congress, the national legislature, approved the establishment of special economic zones in Shenzhen, Zhuhai and Shantou in Guangdong Province and Xiamen in Fujian Province.
Over the past four decades, Shenzhen has been transformed from a small fishing village to a modern metropolis with a population of over 13 million.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005890/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
